Weíre all aware of the evolving law as it relates to pharmaceutical cannabis (and cannabis in general). In the US, some states offer it; others donít. Though itís still against Federal law to buy or sell it, generally speaking cannabis is now more accessible to more people in a variety of forms.
But many people feel uncomfortable purchasing cannabis at a dispensary, preferring a doctor-prescription through a pharmacy. Others want robust evidence through clinical trials that itís safe and effective for their particular condition, along with the approval of the FDA or other regulatory bodies.
These patients may soon get their wish.
CURE Pharmaceutical. a fully integrated life science company committed to improving drug efficacy, safety and the patient experience through its proprietary drug dosage forms and delivery systems, is partnering with numerous organizations such as Technion and Therapix, to develop proven forms of medical cannabis that are easily accessible for patients, including the prospect of pediatric use.
These innovations leverage oral thin film (OTF) that integrates CUREís proprietary CUREfilm technology. This allows for precise use of active Ė and multiple Ė cannabinoid ingredients on one OTF to target multiple conditions, such as leukemia, prostate cancer and sleep disorders.
Not only will this advance the use of pharmaceutical cannabis, but would allow for novel delivery directly through film into the bloodstream, bypassing the GI tract (unlike oral pills) and the potential GI side effects and efficacy dilution typical of pills.
For more information about CURE Pharmaceutical or its CUREfilm technology, contact Euvy Tatunay at [email protected].